Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Pluristem Therapeutics Inc.    PSTI

 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/22/2017 05/23/2017 05/24/2017 05/25/2017 05/26/2017 Date
1.41(c) 1.41(c) 1.38(c) 1.4(c) 1.39(c) Last
312 051 149 148 157 186 43 097 40 754 Volume
+8.46% 0.00% -2.13% +1.45% -0.71% Change
More quotes
Financials ($)
Sales 2017 -
EBIT 2017 -27,8 M
Net income 2017 -27,8 M
Debt 2017 -
Yield 2017 -
Sales 2018 -
EBIT 2018 -33,5 M
Net income 2018 -34,0 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 0
Capi. / Sales2018 0
Capitalization 134 M
More Financials
Company
Pluristem Therapeutics, Inc. is a biotechnology company engages in the provision of cell therapy development.It focuses on cell therapies for the treatment of diseases such as muscle injury, acute radiation syndrome, pulmonary arterial hypertension and others.Its products include PLacental... 
More about the company
Latest news on PLURISTEM THERAPEUTICS INC
05/26 PLURISTEM THERAPEUTICS : The Israeli company protecting against radiation catast..
05/25 PLURISTEM THERAPEUTICS INC. (NASDAQ : PSTI) Files An 8-K Submission of Matters t..
05/25 PLURISTEM THERAPEUTICS INC : Submission of Matters to a Vote of Security Holders..
05/23 PLURISTEM THERAPEUTICS : Provides Shareholder Update on Corporate and Clinical D..
05/22 Pluristem Provides Shareholder Update on Corporate and Clinical Developments
05/18 PLURISTEM THERAPEUTICS : Video for ShareHolders- Non Human Primates Study Result..
05/09 PLURISTEM THERAPEUTICS : reports 3Q loss
05/08 PLURISTEM THERAPEUTICS : Management's Discussion and Analysis of Financial Condi..
05/08 PLURISTEM THERAPEUTICS : A biological solution to the Iranian threat
05/04 PLURISTEM THERAPEUTICS : Announces Promising Results from Non-Human Primate Pilo..
More news
Sector news : Biotechnology & Medical Research - NEC
05/23 UK competition watchdog accuses Merck of obstructing biosimilars
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/22DJAMGEN : Another Gloomy Day for Amgen
05/09 Sanofi pegs U.S. drug price rises to below healthcare inflation
05/09DJVERTEX PHARMACEUTICALS INCORPORATED : Trump's Pick to Lead FDA Has Backing of Bi..
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
05/24Pluristem Therapeutics Inc. $PSTI Rating Reiterated by Maxim Group  
05/23Pluristem Therapeutics's hold rating reiterated at Maxim Group.  
05/22Pluristem Therapeutics Provides Shareholder Update On Corporate And Clinical .. 
05/22$PSTI: Pluristem Therapeutics reports Q3 update
2
05/18Pluristem Therapeutics : Video for ShareHolders- Non Human Primates Study Res.. 
More tweets
Qtime:11
News from SeekingAlpha
05/03 PREMARKET GAINERS AS OF 9 : 05 am
05/03 Pluristem +10% on promising results for PLX-R18
04/11 Can Pluristem Therapeutics Corner The Acute Radiation Syndrome Market?
03/30 Pluristem +5% as talks for Japan JV progress
02/22 Will Pluristem's Acute Radiation Syndrome Trial Results In May Bring Some Pot..
Advertisement
Chart PLURISTEM THERAPEUTICS INC
Duration : Period :
Pluristem Therapeutics Inc Technical Analysis Chart | PSTI | US72940R1023 | 4-Traders
Full-screen chart
Technical analysis trends PLURISTEM THERAPE...
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 3,25 $
Spread / Average Target 134%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Zami Aberman Chairman & Co-Chief Executive Officer
Yaky Yanay President, Co-Chief Executive Officer & Director
Sagi Moran Vice President-Operations
Erez Egozi Chief Financial Officer & Treasurer
Esther Lukasiewicz-Hagai Vice President-Clinical & Medical Affairs
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PLURISTEM THERAPEUTICS..-2.80%134
INCYTE CORPORATION38.04%27 518
QUINTILES IMS HOLDINGS..11.37%18 872
LONZA GROUP AG25.78%15 703
CELLTRION, INC.--.--%10 293
SEATTLE GENETICS, INC.25.11%9 358
More Results